> top > docs > PMC:7156805 > spans > 4576-6298 > annotations

PMC:7156805 / 4576-6298 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
95 216-221 Gene denotes NF-κB Gene:4790
96 527-532 Gene denotes TNF-α Gene:7124
97 833-837 Gene denotes IL-1 Gene:3552
98 873-877 Gene denotes IL-4 Gene:3565
99 970-975 Gene denotes IL-17 Gene:3605
100 1137-1143 Gene denotes IL-17a Gene:3605
101 1180-1186 Gene denotes IL-17a Gene:3605
102 1269-1274 Gene denotes IL-23 Gene:51561
103 1442-1446 Gene denotes PDE4 Gene:5141
104 664-669 Disease denotes fever MESH:D005334
105 1086-1091 Disease denotes fever MESH:D005334
108 1568-1572 Gene denotes PDE4 Gene:5141
109 1542-1547 Gene denotes NF-κB Gene:4790
111 1687-1694 Species denotes patient Tax:9606

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T71 423-426 Body_part denotes DNA http://purl.org/sig/ont/fma/fma74412
T72 696-703 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T73 786-788 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T74 809-811 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T75 833-837 Body_part denotes IL-1 http://purl.org/sig/ont/fma/fma86583
T76 833-835 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T77 873-875 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T78 970-972 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T79 1137-1139 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T80 1180-1182 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T81 1224-1229 Body_part denotes IL-12 http://purl.org/sig/ont/fma/fma86579
T82 1224-1226 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T83 1269-1271 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T84 1309-1317 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T85 1525-1527 Body_part denotes IL http://purl.org/sig/ont/fma/fma86578
T86 1529-1540 Body_part denotes Interleukin http://purl.org/sig/ont/fma/fma86578

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T48 220-221 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T49 1546-1547 http://purl.obolibrary.org/obo/CLO_0001021 denotes B
T50 1565-1566 http://purl.obolibrary.org/obo/CLO_0001021 denotes B

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T32 41-57 Chemical denotes immunomodulators http://purl.obolibrary.org/obo/CHEBI_50846
T33 216-218 Chemical denotes NF http://purl.obolibrary.org/obo/CHEBI_141424|http://purl.obolibrary.org/obo/CHEBI_25573|http://purl.obolibrary.org/obo/CHEBI_1224
T36 363-372 Chemical denotes inhibitor http://purl.obolibrary.org/obo/CHEBI_35222
T37 373-383 Chemical denotes Tacrolimus http://purl.obolibrary.org/obo/CHEBI_61049
T38 384-396 Chemical denotes Cyclosporine http://purl.obolibrary.org/obo/CHEBI_4031
T39 423-426 Chemical denotes DNA http://purl.obolibrary.org/obo/CHEBI_16991
T40 439-452 Chemical denotes Mycophenolate http://purl.obolibrary.org/obo/CHEBI_168396
T41 474-486 Chemical denotes Methotrexate http://purl.obolibrary.org/obo/CHEBI_44185
T42 696-703 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T43 704-714 Chemical denotes Etanercept http://purl.obolibrary.org/obo/CHEBI_4875
T44 786-788 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T46 789-808 Chemical denotes receptor modulators http://purl.obolibrary.org/obo/CHEBI_90710
T47 809-811 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T49 833-835 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T51 873-875 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T53 970-972 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T55 1137-1139 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T57 1180-1182 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T59 1224-1226 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T61 1269-1271 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T63 1525-1527 Chemical denotes IL http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072
T65 1542-1544 Chemical denotes NF http://purl.obolibrary.org/obo/CHEBI_141424|http://purl.obolibrary.org/obo/CHEBI_25573|http://purl.obolibrary.org/obo/CHEBI_1224

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T28 351-362 http://purl.obolibrary.org/obo/GO_0004723 denotes Calcineurin
T29 351-362 http://purl.obolibrary.org/obo/GO_0004722 denotes Calcineurin
T30 414-438 http://purl.obolibrary.org/obo/GO_0008156 denotes Inhibits DNA replication
T31 423-438 http://purl.obolibrary.org/obo/GO_0006260 denotes DNA replication
T32 786-797 http://purl.obolibrary.org/obo/GO_0004896 denotes IL receptor

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T10 664-669 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945
T11 1086-1091 Phenotype denotes fever http://purl.obolibrary.org/obo/HP_0001945

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T19 0-108 Sentence denotes Table I Considerations for commonly used immunomodulators and immunosuppressants for dermatologic conditions
T20 109-179 Sentence denotes Drug class Mechanism of action Drug name Risk Comments/considerations∗
T21 180-206 Sentence denotes Classic immunosuppressants
T22 207-350 Sentence denotes Inhibits NF-κB Corticosteroids Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure
T23 351-383 Sentence denotes Calcineurin inhibitor Tacrolimus
T24 384-396 Sentence denotes Cyclosporine
T25 397-460 Sentence denotes  Antimetabolites Inhibits DNA replication Mycophenolate mofetil
T26 461-473 Sentence denotes Azathioprine
T27 474-486 Sentence denotes Methotrexate
T28 487-503 Sentence denotes Immunomodulators
T29 504-678 Sentence denotes  Monoclonal antibodies TNF-α inhibition Infliximab Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops
T30 679-714 Sentence denotes  Receptor fusion protein Etanercept
T31 715-750 Sentence denotes  Monoclonal antibodies Certolizumab
T32 751-784 Sentence denotes  Monoclonal antibodies Adalimumab
T33 785-838 Sentence denotes  IL receptor modulators IL inhibition Anakinra (IL-1)
T34 839-934 Sentence denotes  Monoclonal antibodies Dupilumab (IL-4) Likely low risk Continue unless severe symptoms present
T35 935-1100 Sentence denotes  Monoclonal antibodies Brodalumab (IL-17) Likely moderate risk Continue if viral symptoms are mild, consider stopping if viral symptoms worsen or high fever develops
T36 1101-1144 Sentence denotes  Monoclonal antibodies Secukinumab (IL-17a)
T37 1145-1187 Sentence denotes  Monoclonal antibodies Ixekizumab (IL-17a)
T38 1188-1233 Sentence denotes  Monoclonal antibodies Ustekinumab (IL-12/23)
T39 1234-1275 Sentence denotes  Monoclonal antibodies Guselkumab (IL-23)
T40 1276-1441 Sentence denotes  Monoclonal antibodies Anti-CD20 antibody Rituximab Likely concerning risk Consider stopping when viral symptoms present especially with known or potential exposure.
T41 1442-1524 Sentence denotes PDE4 inhibition Apremilast Likely low risk Continue unless severe symptoms present
T42 1525-1594 Sentence denotes IL, Interleukin; NF-κB, nuclear factor κB; PDE4, phosphodiesterase 4.
T43 1595-1722 Sentence denotes ∗ General considerations only, medication use should be considered based on each individual patient's risk and disease profile.